Target-mediated drug disposition and dynamics

被引:179
作者
Mager, DE [1 ]
机构
[1] SUNY Buffalo, Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
关键词
target-mediated drug disposition; nonlinear pharmacokinetics; pharmacodynamics; mathematical modeling;
D O I
10.1016/j.bcp.2005.12.041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonlinear pharmacokinetics and pharmacodynamics may result from several capacity-limited processes and often represent complicating factors in characterizing the pharmacological properties of drugs. Target-mediated drug disposition (TMDD) corresponds to a special case wherein a significant proportion of a drug (relative to dose) is bound with high affinity to a pharmacological target, such that this interaction is reflected in the pharma-cokinetic properties of the drug. Dose-dependent effects on apparent pharmacokinetic parameters may manifest, including the steady-state volume of distribution and total systemic clearance. Although a few small molecular weight compounds have been identified to exhibit TMDD, the incidence of TMDD is likely to increase particularly among emerging biotechnology pharmaceuticals. The goal of this commentary is to describe the basic tenets of TMDD and discuss several mathematical modeling approaches for characterizing this phenomenon. Whereas traditional pharmacokinetic/pharmacodynamic models assume that the amount of the drug-target complex is negligible relative to the total amount of drug in the body, integrated mechanism-based models of TMDD incorporate the binding and stoichiometry of drug-target binding. These models may be utilized to infer the time-course of inaccessible system variables, such as the in vivo density of the drug-target complex, and provide a suitable platform for ascertaining the apparent pharmacodynamic implications of TMDD. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 73 条
[41]   Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins [J].
Mahmood, I ;
Green, MD .
CLINICAL PHARMACOKINETICS, 2005, 44 (04) :331-347
[42]   Formation of human IFN-β complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice [J].
McKenna, SD ;
Vergilis, K ;
Arulanandam, ARN ;
Weiser, WY ;
Nabioullin, R ;
Tepper, MA .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2004, 24 (02) :119-129
[43]   ACCUMULATION KINETICS OF DRUGS WITH NON-LINEAR PLASMA-PROTEIN AND TISSUE BINDING CHARACTERISTICS [J].
MCNAMARA, PJ ;
SLATTERY, JT ;
GIBALDI, M ;
LEVY, G .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1979, 7 (04) :397-405
[44]  
Mehvar R, 2000, J PHARM PHARM SCI, V3, P125
[45]   Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen [J].
Meijer, RT ;
Koopmans, RP ;
Ten Berge, IJM ;
Schellekens, PTA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01) :346-353
[46]  
Michaelis L, 1913, BIOCHEM Z, V49, P333
[47]   Wavelet analysis of dynamic PET data:: Application to the parametric imaging of benzodiazepine receptor concentration [J].
Millet, P ;
Ibáñez, V ;
Delforge, J ;
Pappata, S ;
Guimón, J .
NEUROIMAGE, 2000, 11 (05) :458-472
[48]  
MUFSON RA, 1987, BLOOD, V69, P1485
[49]   Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis [J].
Ng, CM ;
Joshi, A ;
Dedrick, RL ;
Garovoy, MR ;
Bauer, RJ .
PHARMACEUTICAL RESEARCH, 2005, 22 (07) :1088-1100
[50]   EFFECT OF SATURABLE BINDING ON THE PHARMACOKINETICS OF DRUGS - A SIMULATION [J].
OIE, S ;
GUENTERT, TW ;
TOZER, TN .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1980, 32 (07) :471-477